Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

We 'shouldn't' test next generation sequencing on metastatic breast cancer patients

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 28.01.19
Views: 278

Prof Matti Aapro - Genolier Cancer Centre, Genolier, Switzerland

Prof Matti Aapro speaks to ecancer at BGICC 2019 in Cairo about a debate covering the testing of Next Generation Sequencing in metastatic breast cancer patients.

He argues against NGS, saying that there is no evidence saying that it has to be done.

Prof Aapro also believes there is not much to learn from NGS compared to standard pathology, and even a molecular signal from NGS is not necessarily enough evidence for a articular drug to be used.

See the opposing view from Prof Edith Perez here

 

Categories:

BGICC 2019

Related videos

follow us

Neutropenia


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation